Prof Hang Quach
Honorary Clinical Professor
Department of Medicine
551 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
DOI: 10.1038/s41408-025-01436-02026
Journal article
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
DOI: 10.1016/S0140-6736(26)01088-32026
Journal article
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
DOI: 10.1182/bloodadvances.20250193232026
Journal article
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
DOI: 10.1200/jco.2026.44.17_suppl.lba75062026
Journal article
Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.
DOI: 10.1200/jco.2026.44.16_suppl.75652026
Journal article
MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).
DOI: 10.1200/jco.2026.44.16_suppl.75072018
Research grants (other domestic)
Novel Immunotherapy Approach for Rescuing Inadequate Responses and Resistance to Treatment for Patients With Multiple Myeloma
RECENT SCHOLARLY WORKS
2026
Journal article
Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.
DOI: 10.1200/jco.2026.44.16_suppl.75632026
Journal article
DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).
DOI: 10.1200/jco.2026.44.16_suppl.75032026
Journal article
Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
DOI: 10.1200/jco.2026.44.16_suppl.75152026
Journal article
Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
DOI: 10.1200/jco.2026.44.16_suppl.7564
RECENT PROJECTS
2014
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma
2013
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma